Gengraf Conversion Study in Stable Renal Allograft Transplant Recipients
Information source: Penang Hospital, Malaysia
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: End Stage Renal Failure
Intervention: Neoral (Drug); Gengraf® capsule containing 25mg or 100mg cyclosporine (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Penang Hospital, Malaysia Official(s) and/or principal investigator(s): Dr.Ong L Meng, MBBS, FRCP, Principal Investigator, Affiliation: Penang Hospital, Ministry of Health Malaysia
Summary
The purpose of this study is to establish the therapeutic equivalence of Gengraf® with the
standard treatment Neoral® for a treatment period of 6 months in stable renal allograft
transplant recipients with respect to drug levels, dosage, and acute graft rejection and
other adverse events.
Clinical Details
Official title: A Randomized, Multi-center, Open Label Trial to Establish the Therapeutic Equivalence Between Neoral® and Gengraf® in Stable Renal Allograft Recipients [Gengraf Conversion Study]
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Serum creatinine level at 12 weeks
Secondary outcome: CsA trough concentration and at 2 hour after CsA administration, at 2 weeks, 6 weeks 12 weeks, 6 months, 9 months and 12 months post randomization.
Detailed description:
The introduction of cyclosporine (CsA) into clinical practice resulted in improvements in
acute renal allograft rejection rate and graft survival in renal transplant patients.
Gengraf a microemulsion formulation of CsA though granted an AB-rated equivalent to Neoral,
because of concerns over the use of generic drugs in transplantation, we undertook this
study to evaluate the clinical efficacy and safety of Gengraf.
We conducted a multicenter, randomized, open labeled study to establish the equivalence
between Gengraf and Neoral in stable renal transplant recipients for a treatment period of 6
months. 6 months post transplant patients with stable graft function and receiving a stable
dose of neoral were recruited into the study. Eligible patients were randomly assigned to
remain on Neoral or convert to an equal milligram-for-milligram dose of Gengraf. The primary
end-point was serum creatinine at 26 weeks.
Eligibility
Minimum age: 18 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Written informed consent obtained from patient or parents/guardian.
2. Patients who are more than 6 months post transplant
3. Stable graft function i. e. serum creatinine less than 300 umol/l
4. Patients currently on a stable dose of capsule Neoral within last one month
Exclusion Criteria:
1. Multiple organ transplantation
2. Pregnant or nursing woman, or women of childbearing potential without an effective
method of birth control. Effective birth control methods are oral contraception,
Norplant, surgical sterilization, Intra Uterine Device or diaphragms in conjunction
with spermicidal foam and condom on the male partner.
3. Participation in any drug trial in which the patient received an investigational drug
within 30 days preceding the screening phase of this study.
4. Those persons directly involved in the conduct of the study.
5. Active infection at the time of screening for enrollment into trial.
6. Acute graft rejection within the past 3 months
7. Mentally unstable or history of mental diseases
8. History of drug or alcohol abuse within the past 2 years.
9. History of non-compliance to medical regimen and patients who are unwilling or unable
to comply with the protocol.
10. Decompensated liver disease
11. Any serious medical conditions or disability, which in the opinion of the
investigator, would interfere with treatment or assessment or preclude completion of
this study
Locations and Contacts
Clinical Research Centre, Penang Hospital, George Town, Penang 10990, Malaysia
Additional Information
Starting date: November 2004
Last updated: November 15, 2013
|